aluates Reports

$ 0.0

Automative

Global Neurotrophic Keratitis Market Research Report 2025

Published Date: July 2025

Report Code: QYRE-Auto-1W6125

Global Neurotrophic Keratitis Market Insights and Forecast to 2028

BUY CHAPTERS

Global Neurotrophic Keratitis Market Research Report 2025

Code: QYRE-Auto-1W6125

Report

July 2025

Pages:89

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Dompe Farmaceutici

Allergan plc

ReGenTree, LLC, Alcon,

Bausch & Lomb Incorporated (Bausch Health Companies Inc.),

CONTACARE,

OHTO Pharmaceutical Co., Ltd.,

Pfizer Inc

Neuroptika

Santen Pharmaceutical Co., Ltd.

Johnson & Johnson

Zhejiang CONBA Pharmaceutical Co., Ltd.

China

Grand Pharma (China) Co., Ltd., and

Neurotrophic Keratitis Market Size

The global market for Neurotrophic Keratitis was valued at US$ 1011 million in the year 2024 and is projected to reach a revised size of US$ 1749 million by 2031, growing at a CAGR of 8.3% during the forecast period.

Neurotrophic Keratitis Market

Neurotrophic keratitis (NK) is a degenerative disease of the cornea caused by damage of the trigeminal nerve, which results in impairment of corneal sensitivity, spontaneous corneal epithelium breakdown, poor corneal healing and development of corneal ulceration, melting and perforation.

Neurotrophic Keratitis (NK) is a rare eye condition that affects the cornea due to damage or dysfunction of the trigeminal nerve, which is responsible for providing sensation to the cornea. This condition can lead to reduced corneal sensitivity, impaired healing, and potential vision loss.

This report aims to provide a comprehensive presentation of the global market for Neurotrophic Keratitis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurotrophic Keratitis.

The Neurotrophic Keratitis market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neurotrophic Keratitis market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Neurotrophic Keratitis companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Neurotrophic Keratitis Market Report

Report Metric	Details
Report Name	Neurotrophic Keratitis Market
Accounted market size in year	US$ 1011 million
Forecasted market size in 2031	US$ 1749 million
CAGR	8.3%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Drugs Surgical Intervention
Segment by Application	Hospital Clinic
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Dompe farmaceutici S.p.A.,, Allergan,, ReGenTree, LLC, Alcon,, Bausch & Lomb Incorporated (Bausch Health Companies Inc.),, CONTACARE,, OHTO Pharmaceutical Co., Ltd.,, Pfizer, Inc.,, Neuroptika, Santen Pharmaceutical Co., Ltd.,, Johnson & Johnson,, Grand Pharma (China) Co., Ltd., and, Zhejiang CONBA Pharmaceutical Co., Ltd.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neurotrophic Keratitis company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Neurotrophic Keratitis Market growing?

Ans: The Neurotrophic Keratitis Market witnessing a CAGR of 8.3% during the forecast period 2025-2031.

What is the Neurotrophic Keratitis Market size in 2031?

Ans: The Neurotrophic Keratitis Market size in 2031 will be US$ 1749 million.

Who are the main players in the Neurotrophic Keratitis Market report?

Ans: The main players in the Neurotrophic Keratitis Market are Dompe farmaceutici S.p.A.,, Allergan,, ReGenTree, LLC, Alcon,, Bausch & Lomb Incorporated (Bausch Health Companies Inc.),, CONTACARE,, OHTO Pharmaceutical Co., Ltd.,, Pfizer, Inc.,, Neuroptika, Santen Pharmaceutical Co., Ltd.,, Johnson & Johnson,, Grand Pharma (China) Co., Ltd., and, Zhejiang CONBA Pharmaceutical Co., Ltd.

What are the Application segmentation covered in the Neurotrophic Keratitis Market report?

Ans: The Applications covered in the Neurotrophic Keratitis Market report are Hospital, Clinic

What are the Type segmentation covered in the Neurotrophic Keratitis Market report?

Ans: The Types covered in the Neurotrophic Keratitis Market report are Drugs, Surgical Intervention

Recommended Reports

Ophthalmic Treatments

Neurodegenerative Solutions

Retinal Disorders

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Neurotrophic Keratitis Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Drugs

1.2.3 Surgical Intervention

1.3 Market by Application

1.3.1 Global Neurotrophic Keratitis Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital

1.3.3 Clinic

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Neurotrophic Keratitis Market Perspective (2020-2031)

2.2 Global Neurotrophic Keratitis Growth Trends by Region

2.2.1 Global Neurotrophic Keratitis Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Neurotrophic Keratitis Historic Market Size by Region (2020-2025)

2.2.3 Neurotrophic Keratitis Forecasted Market Size by Region (2026-2031)

2.3 Neurotrophic Keratitis Market Dynamics

2.3.1 Neurotrophic Keratitis Industry Trends

2.3.2 Neurotrophic Keratitis Market Drivers

2.3.3 Neurotrophic Keratitis Market Challenges

2.3.4 Neurotrophic Keratitis Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Neurotrophic Keratitis Players by Revenue

3.1.1 Global Top Neurotrophic Keratitis Players by Revenue (2020-2025)

3.1.2 Global Neurotrophic Keratitis Revenue Market Share by Players (2020-2025)

3.2 Global Neurotrophic Keratitis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Neurotrophic Keratitis Revenue

3.4 Global Neurotrophic Keratitis Market Concentration Ratio

3.4.1 Global Neurotrophic Keratitis Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Neurotrophic Keratitis Revenue in 2024

3.5 Global Key Players of Neurotrophic Keratitis Head office and Area Served

3.6 Global Key Players of Neurotrophic Keratitis, Product and Application

3.7 Global Key Players of Neurotrophic Keratitis, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Neurotrophic Keratitis Breakdown Data by Type

4.1 Global Neurotrophic Keratitis Historic Market Size by Type (2020-2025)

4.2 Global Neurotrophic Keratitis Forecasted Market Size by Type (2026-2031)

5 Neurotrophic Keratitis Breakdown Data by Application

5.1 Global Neurotrophic Keratitis Historic Market Size by Application (2020-2025)

5.2 Global Neurotrophic Keratitis Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Neurotrophic Keratitis Market Size (2020-2031)

6.2 North America Neurotrophic Keratitis Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Neurotrophic Keratitis Market Size by Country (2020-2025)

6.4 North America Neurotrophic Keratitis Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Neurotrophic Keratitis Market Size (2020-2031)

7.2 Europe Neurotrophic Keratitis Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Neurotrophic Keratitis Market Size by Country (2020-2025)

7.4 Europe Neurotrophic Keratitis Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Neurotrophic Keratitis Market Size (2020-2031)

8.2 Asia-Pacific Neurotrophic Keratitis Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Neurotrophic Keratitis Market Size by Region (2020-2025)

8.4 Asia-Pacific Neurotrophic Keratitis Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Neurotrophic Keratitis Market Size (2020-2031)

9.2 Latin America Neurotrophic Keratitis Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Neurotrophic Keratitis Market Size by Country (2020-2025)

9.4 Latin America Neurotrophic Keratitis Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Neurotrophic Keratitis Market Size (2020-2031)

10.2 Middle East & Africa Neurotrophic Keratitis Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Neurotrophic Keratitis Market Size by Country (2020-2025)

10.4 Middle East & Africa Neurotrophic Keratitis Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Dompe farmaceutici S.p.A.,

11.1.1 Dompe farmaceutici S.p.A., Company Details

11.1.2 Dompe farmaceutici S.p.A., Business Overview

11.1.3 Dompe farmaceutici S.p.A., Neurotrophic Keratitis Introduction

11.1.4 Dompe farmaceutici S.p.A., Revenue in Neurotrophic Keratitis Business (2020-2025)

11.1.5 Dompe farmaceutici S.p.A., Recent Development

11.2 Allergan,

11.2.1 Allergan, Company Details

11.2.2 Allergan, Business Overview

11.2.3 Allergan, Neurotrophic Keratitis Introduction

11.2.4 Allergan, Revenue in Neurotrophic Keratitis Business (2020-2025)

11.2.5 Allergan, Recent Development

11.3 ReGenTree, LLC, Alcon,

11.3.1 ReGenTree, LLC, Alcon, Company Details

11.3.2 ReGenTree, LLC, Alcon, Business Overview

11.3.3 ReGenTree, LLC, Alcon, Neurotrophic Keratitis Introduction

11.3.4 ReGenTree, LLC, Alcon, Revenue in Neurotrophic Keratitis Business (2020-2025)

11.3.5 ReGenTree, LLC, Alcon, Recent Development

11.4 Bausch & Lomb Incorporated (Bausch Health Companies Inc.),

11.4.1 Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Company Details

11.4.2 Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Business Overview

11.4.3 Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Neurotrophic Keratitis Introduction

11.4.4 Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Revenue in Neurotrophic Keratitis Business (2020-2025)

11.4.5 Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Recent Development

11.5 CONTACARE,

11.5.1 CONTACARE, Company Details

11.5.2 CONTACARE, Business Overview

11.5.3 CONTACARE, Neurotrophic Keratitis Introduction

11.5.4 CONTACARE, Revenue in Neurotrophic Keratitis Business (2020-2025)

11.5.5 CONTACARE, Recent Development

11.6 OHTO Pharmaceutical Co., Ltd.,

11.6.1 OHTO Pharmaceutical Co., Ltd., Company Details

11.6.2 OHTO Pharmaceutical Co., Ltd., Business Overview

11.6.3 OHTO Pharmaceutical Co., Ltd., Neurotrophic Keratitis Introduction

11.6.4 OHTO Pharmaceutical Co., Ltd., Revenue in Neurotrophic Keratitis Business (2020-2025)

11.6.5 OHTO Pharmaceutical Co., Ltd., Recent Development

11.7 Pfizer, Inc.,

11.7.1 Pfizer, Inc., Company Details

11.7.2 Pfizer, Inc., Business Overview

11.7.3 Pfizer, Inc., Neurotrophic Keratitis Introduction

11.7.4 Pfizer, Inc., Revenue in Neurotrophic Keratitis Business (2020-2025)

11.7.5 Pfizer, Inc., Recent Development

11.8 Neuroptika

11.8.1 Neuroptika Company Details

11.8.2 Neuroptika Business Overview

11.8.3 Neuroptika Neurotrophic Keratitis Introduction

11.8.4 Neuroptika Revenue in Neurotrophic Keratitis Business (2020-2025)

11.8.5 Neuroptika Recent Development

11.9 Santen Pharmaceutical Co., Ltd.,

11.9.1 Santen Pharmaceutical Co., Ltd., Company Details

11.9.2 Santen Pharmaceutical Co., Ltd., Business Overview

11.9.3 Santen Pharmaceutical Co., Ltd., Neurotrophic Keratitis Introduction

11.9.4 Santen Pharmaceutical Co., Ltd., Revenue in Neurotrophic Keratitis Business (2020-2025)

11.9.5 Santen Pharmaceutical Co., Ltd., Recent Development

11.10 Johnson & Johnson,

11.10.1 Johnson & Johnson, Company Details

11.10.2 Johnson & Johnson, Business Overview

11.10.3 Johnson & Johnson, Neurotrophic Keratitis Introduction

11.10.4 Johnson & Johnson, Revenue in Neurotrophic Keratitis Business (2020-2025)

11.10.5 Johnson & Johnson, Recent Development

11.11 Grand Pharma (China) Co., Ltd., and

11.11.1 Grand Pharma (China) Co., Ltd., and Company Details

11.11.2 Grand Pharma (China) Co., Ltd., and Business Overview

11.11.3 Grand Pharma (China) Co., Ltd., and Neurotrophic Keratitis Introduction

11.11.4 Grand Pharma (China) Co., Ltd., and Revenue in Neurotrophic Keratitis Business (2020-2025)

11.11.5 Grand Pharma (China) Co., Ltd., and Recent Development

11.12 Zhejiang CONBA Pharmaceutical Co., Ltd.

11.12.1 Zhejiang CONBA Pharmaceutical Co., Ltd. Company Details

11.12.2 Zhejiang CONBA Pharmaceutical Co., Ltd. Business Overview

11.12.3 Zhejiang CONBA Pharmaceutical Co., Ltd. Neurotrophic Keratitis Introduction

11.12.4 Zhejiang CONBA Pharmaceutical Co., Ltd. Revenue in Neurotrophic Keratitis Business (2020-2025)

11.12.5 Zhejiang CONBA Pharmaceutical Co., Ltd. Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Dompe Farmaceutici

Allergan plc

ReGenTree, LLC, Alcon,

Bausch & Lomb Incorporated (Bausch Health Companies Inc.),

CONTACARE,

OHTO Pharmaceutical Co., Ltd.,

Pfizer Inc

Neuroptika

Santen Pharmaceutical Co., Ltd.

Johnson & Johnson

Zhejiang CONBA Pharmaceutical Co., Ltd.

China

Grand Pharma (China) Co., Ltd., and

List of Tables

Table 1. Global Neurotrophic Keratitis Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Drugs

Table 3. Key Players of Surgical Intervention

Table 4. Global Neurotrophic Keratitis Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global Neurotrophic Keratitis Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Neurotrophic Keratitis Market Size by Region (2020-2025) & (US$ Million)

Table 7. Global Neurotrophic Keratitis Market Share by Region (2020-2025)

Table 8. Global Neurotrophic Keratitis Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 9. Global Neurotrophic Keratitis Market Share by Region (2026-2031)

Table 10. Neurotrophic Keratitis Market Trends

Table 11. Neurotrophic Keratitis Market Drivers

Table 12. Neurotrophic Keratitis Market Challenges

Table 13. Neurotrophic Keratitis Market Restraints

Table 14. Global Neurotrophic Keratitis Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global Neurotrophic Keratitis Market Share by Players (2020-2025)

Table 16. Global Top Neurotrophic Keratitis Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurotrophic Keratitis as of 2024)

Table 17. Ranking of Global Top Neurotrophic Keratitis Companies by Revenue (US$ Million) in 2024

Table 18. Global 5 Largest Players Market Share by Neurotrophic Keratitis Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of Neurotrophic Keratitis, Headquarters and Area Served

Table 20. Global Key Players of Neurotrophic Keratitis, Product and Application

Table 21. Global Key Players of Neurotrophic Keratitis, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Neurotrophic Keratitis Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global Neurotrophic Keratitis Revenue Market Share by Type (2020-2025)

Table 25. Global Neurotrophic Keratitis Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global Neurotrophic Keratitis Revenue Market Share by Type (2026-2031)

Table 27. Global Neurotrophic Keratitis Market Size by Application (2020-2025) & (US$ Million)

Table 28. Global Neurotrophic Keratitis Revenue Market Share by Application (2020-2025)

Table 29. Global Neurotrophic Keratitis Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 30. Global Neurotrophic Keratitis Revenue Market Share by Application (2026-2031)

Table 31. North America Neurotrophic Keratitis Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America Neurotrophic Keratitis Market Size by Country (2020-2025) & (US$ Million)

Table 33. North America Neurotrophic Keratitis Market Size by Country (2026-2031) & (US$ Million)

Table 34. Europe Neurotrophic Keratitis Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. Europe Neurotrophic Keratitis Market Size by Country (2020-2025) & (US$ Million)

Table 36. Europe Neurotrophic Keratitis Market Size by Country (2026-2031) & (US$ Million)

Table 37. Asia-Pacific Neurotrophic Keratitis Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 38. Asia-Pacific Neurotrophic Keratitis Market Size by Region (2020-2025) & (US$ Million)

Table 39. Asia-Pacific Neurotrophic Keratitis Market Size by Region (2026-2031) & (US$ Million)

Table 40. Latin America Neurotrophic Keratitis Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 41. Latin America Neurotrophic Keratitis Market Size by Country (2020-2025) & (US$ Million)

Table 42. Latin America Neurotrophic Keratitis Market Size by Country (2026-2031) & (US$ Million)

Table 43. Middle East & Africa Neurotrophic Keratitis Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Middle East & Africa Neurotrophic Keratitis Market Size by Country (2020-2025) & (US$ Million)

Table 45. Middle East & Africa Neurotrophic Keratitis Market Size by Country (2026-2031) & (US$ Million)

Table 46. Dompe farmaceutici S.p.A., Company Details

Table 47. Dompe farmaceutici S.p.A., Business Overview

Table 48. Dompe farmaceutici S.p.A., Neurotrophic Keratitis Product

Table 49. Dompe farmaceutici S.p.A., Revenue in Neurotrophic Keratitis Business (2020-2025) & (US$ Million)

Table 50. Dompe farmaceutici S.p.A., Recent Development

Table 51. Allergan, Company Details

Table 52. Allergan, Business Overview

Table 53. Allergan, Neurotrophic Keratitis Product

Table 54. Allergan, Revenue in Neurotrophic Keratitis Business (2020-2025) & (US$ Million)

Table 55. Allergan, Recent Development

Table 56. ReGenTree, LLC, Alcon, Company Details

Table 57. ReGenTree, LLC, Alcon, Business Overview

Table 58. ReGenTree, LLC, Alcon, Neurotrophic Keratitis Product

Table 59. ReGenTree, LLC, Alcon, Revenue in Neurotrophic Keratitis Business (2020-2025) & (US$ Million)

Table 60. ReGenTree, LLC, Alcon, Recent Development

Table 61. Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Company Details

Table 62. Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Business Overview

Table 63. Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Neurotrophic Keratitis Product

Table 64. Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Revenue in Neurotrophic Keratitis Business (2020-2025) & (US$ Million)

Table 65. Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Recent Development

Table 66. CONTACARE, Company Details

Table 67. CONTACARE, Business Overview

Table 68. CONTACARE, Neurotrophic Keratitis Product

Table 69. CONTACARE, Revenue in Neurotrophic Keratitis Business (2020-2025) & (US$ Million)

Table 70. CONTACARE, Recent Development

Table 71. OHTO Pharmaceutical Co., Ltd., Company Details

Table 72. OHTO Pharmaceutical Co., Ltd., Business Overview

Table 73. OHTO Pharmaceutical Co., Ltd., Neurotrophic Keratitis Product

Table 74. OHTO Pharmaceutical Co., Ltd., Revenue in Neurotrophic Keratitis Business (2020-2025) & (US$ Million)

Table 75. OHTO Pharmaceutical Co., Ltd., Recent Development

Table 76. Pfizer, Inc., Company Details

Table 77. Pfizer, Inc., Business Overview

Table 78. Pfizer, Inc., Neurotrophic Keratitis Product

Table 79. Pfizer, Inc., Revenue in Neurotrophic Keratitis Business (2020-2025) & (US$ Million)

Table 80. Pfizer, Inc., Recent Development

Table 81. Neuroptika Company Details

Table 82. Neuroptika Business Overview

Table 83. Neuroptika Neurotrophic Keratitis Product

Table 84. Neuroptika Revenue in Neurotrophic Keratitis Business (2020-2025) & (US$ Million)

Table 85. Neuroptika Recent Development

Table 86. Santen Pharmaceutical Co., Ltd., Company Details

Table 87. Santen Pharmaceutical Co., Ltd., Business Overview

Table 88. Santen Pharmaceutical Co., Ltd., Neurotrophic Keratitis Product

Table 89. Santen Pharmaceutical Co., Ltd., Revenue in Neurotrophic Keratitis Business (2020-2025) & (US$ Million)

Table 90. Santen Pharmaceutical Co., Ltd., Recent Development

Table 91. Johnson & Johnson, Company Details

Table 92. Johnson & Johnson, Business Overview

Table 93. Johnson & Johnson, Neurotrophic Keratitis Product

Table 94. Johnson & Johnson, Revenue in Neurotrophic Keratitis Business (2020-2025) & (US$ Million)

Table 95. Johnson & Johnson, Recent Development

Table 96. Grand Pharma (China) Co., Ltd., and Company Details

Table 97. Grand Pharma (China) Co., Ltd., and Business Overview

Table 98. Grand Pharma (China) Co., Ltd., and Neurotrophic Keratitis Product

Table 99. Grand Pharma (China) Co., Ltd., and Revenue in Neurotrophic Keratitis Business (2020-2025) & (US$ Million)

Table 100. Grand Pharma (China) Co., Ltd., and Recent Development

Table 101. Zhejiang CONBA Pharmaceutical Co., Ltd. Company Details

Table 102. Zhejiang CONBA Pharmaceutical Co., Ltd. Business Overview

Table 103. Zhejiang CONBA Pharmaceutical Co., Ltd. Neurotrophic Keratitis Product

Table 104. Zhejiang CONBA Pharmaceutical Co., Ltd. Revenue in Neurotrophic Keratitis Business (2020-2025) & (US$ Million)

Table 105. Zhejiang CONBA Pharmaceutical Co., Ltd. Recent Development

Table 106. Research Programs/Design for This Report

Table 107. Key Data Information from Secondary Sources

Table 108. Key Data Information from Primary Sources

Table 109. Authors List of This Report

List of Figures

Figure 1. Neurotrophic Keratitis Picture

Figure 2. Global Neurotrophic Keratitis Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Neurotrophic Keratitis Market Share by Type: 2024 VS 2031

Figure 4. Drugs Features

Figure 5. Surgical Intervention Features

Figure 6. Global Neurotrophic Keratitis Market Size by Application (2020-2031) & (US$ Million)

Figure 7. Global Neurotrophic Keratitis Market Share by Application: 2024 VS 2031

Figure 8. Hospital Case Studies

Figure 9. Clinic Case Studies

Figure 10. Neurotrophic Keratitis Report Years Considered

Figure 11. Global Neurotrophic Keratitis Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 12. Global Neurotrophic Keratitis Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 13. Global Neurotrophic Keratitis Market Share by Region: 2024 VS 2031

Figure 14. Global Neurotrophic Keratitis Market Share by Players in 2024

Figure 15. Global Top Neurotrophic Keratitis Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurotrophic Keratitis as of 2024)

Figure 16. The Top 10 and 5 Players Market Share by Neurotrophic Keratitis Revenue in 2024

Figure 17. North America Neurotrophic Keratitis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 18. North America Neurotrophic Keratitis Market Share by Country (2020-2031)

Figure 19. United States Neurotrophic Keratitis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 20. Canada Neurotrophic Keratitis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. Europe Neurotrophic Keratitis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Europe Neurotrophic Keratitis Market Share by Country (2020-2031)

Figure 23. Germany Neurotrophic Keratitis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. France Neurotrophic Keratitis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. U.K. Neurotrophic Keratitis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Italy Neurotrophic Keratitis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Russia Neurotrophic Keratitis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Nordic Countries Neurotrophic Keratitis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Asia-Pacific Neurotrophic Keratitis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Asia-Pacific Neurotrophic Keratitis Market Share by Region (2020-2031)

Figure 31. China Neurotrophic Keratitis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Japan Neurotrophic Keratitis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. South Korea Neurotrophic Keratitis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Southeast Asia Neurotrophic Keratitis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. India Neurotrophic Keratitis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Australia Neurotrophic Keratitis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Latin America Neurotrophic Keratitis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Latin America Neurotrophic Keratitis Market Share by Country (2020-2031)

Figure 39. Mexico Neurotrophic Keratitis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Brazil Neurotrophic Keratitis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Middle East & Africa Neurotrophic Keratitis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Middle East & Africa Neurotrophic Keratitis Market Share by Country (2020-2031)

Figure 43. Turkey Neurotrophic Keratitis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Saudi Arabia Neurotrophic Keratitis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. UAE Neurotrophic Keratitis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Dompe farmaceutici S.p.A., Revenue Growth Rate in Neurotrophic Keratitis Business (2020-2025)

Figure 47. Allergan, Revenue Growth Rate in Neurotrophic Keratitis Business (2020-2025)

Figure 48. ReGenTree, LLC, Alcon, Revenue Growth Rate in Neurotrophic Keratitis Business (2020-2025)

Figure 49. Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Revenue Growth Rate in Neurotrophic Keratitis Business (2020-2025)

Figure 50. CONTACARE, Revenue Growth Rate in Neurotrophic Keratitis Business (2020-2025)

Figure 51. OHTO Pharmaceutical Co., Ltd., Revenue Growth Rate in Neurotrophic Keratitis Business (2020-2025)

Figure 52. Pfizer, Inc., Revenue Growth Rate in Neurotrophic Keratitis Business (2020-2025)

Figure 53. Neuroptika Revenue Growth Rate in Neurotrophic Keratitis Business (2020-2025)

Figure 54. Santen Pharmaceutical Co., Ltd., Revenue Growth Rate in Neurotrophic Keratitis Business (2020-2025)

Figure 55. Johnson & Johnson, Revenue Growth Rate in Neurotrophic Keratitis Business (2020-2025)

Figure 56. Grand Pharma (China) Co., Ltd., and Revenue Growth Rate in Neurotrophic Keratitis Business (2020-2025)

Figure 57. Zhejiang CONBA Pharmaceutical Co., Ltd. Revenue Growth Rate in Neurotrophic Keratitis Business (2020-2025)

Figure 58. Bottom-up and Top-down Approaches for This Report

Figure 59. Data Triangulation

Figure 60. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Neurotrophic Keratitis Treatment Market Insights Forecast to 2030

Global Orthokeratology Market Insights Forecast to 2030

Global Orthokeratology Lens Market Insights Forecast to 2030

Superficial Punctate Keratitis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Ortho K Lens Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Vernal Keratoconjunctivitis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Herpes Simplex Keratitis Drug Market Insights Forecast to 2030

Herpes Simplex Keratitis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Corneal Repair Medicine Market Research Report 2024

Corneal Ulcer Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Epidemic Keratoconjunctivitis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Orthokeratologylens Market Research Report 2025

Global Ophthalmology Disorders Drug Market Insights Forecast to 2030

Neuromyelitis Optic Spectrum Disorder Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Implantable Artificial Cornea Market Research Report 2024

Global Retinitis Pigmentosa Retinitis Market Insights Forecast to 2030

Global Fungal Keratitis Medicine Market Research Report 2024

Corneal Implantable Devices Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Collar Button Artificial Cornea Market Research Report 2024

RELATED REPORTS

Global High Acuity Care Service Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-5D18285

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global mHealth (Mobile Health) Services Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-18B6151

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Resin Lenses Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-21S7871

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Mobile Medical Imaging Services Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-16Q6154

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions